Form 4: Neurogene Director Robert Keith Woods Granted Stock Options

Neurogene Inc. Director Robert Keith Woods was granted 12,050 non-qualified stock options with an exercise price of $20.40, vesting monthly over one year.

Summary

• Robert Keith Woods, a Director of Neurogene Inc. (NGNE), was granted 12,050 non-qualified stock options.
• The transaction date for this grant was June 12, 2025.
• The exercise price for these options is $20.40 per share.
• The options will vest as to 1/12 of the total shares monthly, beginning July 12, 2025, and will be fully vested by June 12, 2026.
• Vesting is contingent upon Mr. Woods' continued provision of service to Neurogene Inc. on each vesting date.
• The options have an expiration date of June 12, 2035.
• Following this transaction, Mr. Woods beneficially owns 12,050 derivative securities (stock options) directly.
• A Power of Attorney was executed on June 12, 2025, authorizing specific individuals to prepare and file SEC Forms 3, 4, and 5 on behalf of Robert Keith Woods.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive event as it aligns management's interests with shareholders. However, it is a routine compensation event and not indicative of extraordinary news, hence a moderately positive score.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• This is a standard form of compensation for directors, indicating ongoing commitment and engagement with the company.

Future Outlook

The vesting schedule of the stock options indicates an expectation of continued service from Director Robert Keith Woods to Neurogene Inc. through at least June 12, 2026.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, common across all industries, particularly in the biotechnology sector where equity compensation is a standard practice to attract and retain talent.

Corporate Governance

Related Party Transactions

• The grant of 12,050 non-qualified stock options to Robert Keith Woods, a Director of Neurogene Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The option grant aligns the director's interests with shareholder value creation, as the options gain value if the stock price increases.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The stock options will continue to vest monthly until fully vested on June 12, 2026, subject to the director's continued service.

Key Dates

Recommendation

Keywords

Neurogene Inc., NGNE, stock option, Form 4, insider transaction, director compensation, equity grant, Robert Keith Woods